PHAR | Pharming Group N.V. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	9.08 - 9.26
52 Week Range	6.65 - 13.20
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	3,798
Average Volume	7,255
Shares Outstanding	67,835,400
Market Cap	6,173,021,400
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-12-23

Valuation
Profitability
Growth
Health
P/E Ratio	-33.70
Forward P/E Ratio	N/A
EPS	-0.27
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	382
Country	Netherlands
Website	PHAR

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

PHAR's peers: GLSH, ELYM, GNTA, OPT, PRDS, MLYS, ANEB, JANX, RZLT, LIAN, FENC, LRMR, VRCA, FIXX, MOLN, PRTC, ACRV

*Chart delayed

Analyzing fundamentals for PHAR we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is weak. For more detailed analysis please see PHAR Fundamentals page.

Watching at PHAR technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on PHAR Technicals page.